An observational study in Type 1 Diabetes Mellitus, sponsored by Assiut University. Not yet recruiting. Open to participants aged 8 Years to 15 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Mellitus, Type 1 by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Assiut University.
Among the 11 studies in Diabetes Mellitus, Type 1 by Assiut University, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, and was the 7th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →7 of the 11 studies in Diabetes Mellitus, Type 1 by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages up to 18 · Healthy volunteers
Assiut University
Ages 18–80
Assiut University
Ages 1–18 · Healthy volunteers
Assiut University
Ages 1–18
Assiut University
Ages 2–18
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 8 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 220 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 100 across the 1 interventional studies, 115 across the 10 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Diabetes Mellitus, Type 1 by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07845175Assiut UniversityGastrointestinal Symptoms in Children With Type 1 Diabetes | 2027-09-26 |
| NCT07476248Assiut UniversityThe Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus | 2027-10-01 |
| NCT07807553Assiut UniversityLiver Function Test Abnormalities in Pediatric Type 1 Diabetes | 2027-10-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes Mellitus, Type 1 by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aimed to assess the prevalence of psychiatric comorbidities in children and adolescents with diabetes mellitus type 1.
Assessing the impact of diabetes mellitus type 1 on quality of life. And determine the effect of associated factors on the development of psychiatric comorbidities and on quality of life in diabetes mellitus type 1.
Type 1 diabetes mellitus (TDM) is a chronic autoimmune disease. that affected carbohydrate metabolism and caused by insulin insufficiency resulting in increased blood glucose. It's one of the most common endocrine and metabolic conditions in childhood. There's 9 million people live with T1DM worldwide according to International Diabetes Federation. In Egypt, 1 in 98 families are impacted and the disease is growing at 6.7% each year. Living with T1DM has been associated with a significant impact on a person's social, mental, and psychological quality of life (QoL). as the individual must adopt blood glucose monitoring, use of injections or diabetes technology for insulin regulation, diet restrictions, and exercise. Also, there's increased risk of developing micro-and macro-vascular complications that result in morbidity and mortality in Long-term uncontrolled DM. therefore, these children and adolescents with T1DM have an increased risk of psychiatric comorbidities like depression, anxiety and sleep disorders, depression is one of the most common disorders. They appear to have a greater incidence of depression, anxiety and poor health-related quality of life (HRQoL) compared to their healthy peers. This is associated with suboptimal diabetes outcomes and better metabolic control has been found to correlate with better quality of life. This occurs especially when diagnosed at earlier age of onset, history of severe hypoglycemia and chronic hyperglycemia. There are no available studies that assess the presence of psychiatric comorbidities in T1DM in our locality.
Children and adolescent Patients with type 1 diabetes medllitus aged 8-15 years old.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The prevalence of psychiatric comorbidities in children and adolescents with diabetes mellitus type 1.
This outcome will be measured using: The Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime (K-SADS-PL) version
Time frame: 2 years
the prevalence of depression, anxiety and sleep disorder in children and adolescents with diabetes mellitus type 1
this outcome will be measured using: 1. Children's Depression Inventory 2 Self Report-Short (CDI-2) (12) 2. The Spence Children's Anxiety Scale 3. Children's Sleep Habits Questionnaire (CSHQ)
Time frame: 2 years
The impact of diabetes mellitus type 1 on quality of life.
This outcome will be measured using: Pediatric quality of life inventory 4.0 genetic Core scale.
Time frame: 2 years
No study locations are listed for this record.
Plan to share: No
Start is estimated for Oct 2024; primary completion for Sep 2026, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.